116 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
9 May 24
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
4:05pm
to enroll and dose patients for treatment with mCRPC. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity
8-K
EX-99.1
9v2hs9qb
9 Nov 23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
ktsaw rneg
10 Aug 23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
w56fm0s9h8
4 May 23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
bdeil37zkt43c54
3 Nov 22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
4:17pm
8-K
EX-99.1
s125 m2uyaxw
5 May 22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
0j6c3nl yb
10 Mar 22
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
4:15pm
424B5
h3owtzx18hl4qfos3rkx
17 Dec 21
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
kqorwk8w763z9m
4 Nov 21
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
4:01pm
8-K
EX-99.1
dbunovq9vushgimrp18t
5 Aug 21
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
4:00pm